Dr Lal Pathlabs, Metropolis Healthcare shares fall over 2% as Amazon India launches 'Amazon Diagnostics'; key things to know

In the opening deals, Dr Lal Pathlabs slipped as much as 2.24% to ₹2,841.70, while Metropolis Healthcare shares declined as much as 2.21% to ₹1,686 apiece on the NSE.

The service, being offered in collaboration with Orange Health Labs, will be available in Bengaluru, Delhi, Gurgaon, Noida, Mumbai, and Hyderabad, across over 450 PIN codes, the company said in a statement.

With this addition, Amazon has now integrated its existing pharmacy and clinic services under Amazon Medical.

"This expansion strengthens the foundation of Amazon Medical by building on the existing service of Pharmacy and Clinic. With Amazon Pharmacy, customers get access to a wide range of prescription medications and healthcare essentials, along with a free telemedicine consultation service and delivery benefits for Prime and non-Prime members. Amazon Clinic enables customers to consult licensed doctors for a range of primary healthcare needs through a seamless digital experience," Amazon said.

Dr Lal Pathlabs, Metropolis Healthcare shares in focus

Shares of existing players in the space are expected to trade with some cuts. given the increase in competition with the entry of Amazon India.

Dr Lal Pathlabs was founded in 1949 by Major S K Lal. Between 2005 and 2010, Dr Lal PathLabs established a National Reference Lab in Delhi, marking a significant achievement in the company’s history.

Dr Lal PathLabs Q4 FY25 Results

The company reported an 81.4% year-on-year (YoY) surge in fourth-quarter net profit (Q4 FY25), exceeding analyst expectations, fuelled by robust diagnostic volumes, expanded network reach, and improved operational efficiency.

Consolidated net profit for the quarter ended March 31, 2025, climbed to ₹155 crore from ₹85 crore a year earlier. The profit after tax (PAT) margin improved to 25.8% from 15.6% in Q4 FY24.

Revenue from operations rose 10.5% YoY to ₹603 crore, as per a report by CNBC-TV18.

Metropolis Healthcare Q4 FY25 Results

Metropolis Healthcare said its consolidated net profit declined 19% to ₹29 crore in the fourth quarter ended March quarter 2025 (Q4 FY25).

The diagnostics chain had reported a net profit of ₹36 crore for the January-March period of FY24.

Revenue from operations rose to ₹345 crore in the period under review from ₹331 crore in the year-ago period, Metropolis Healthcare said in a regulatory filing.

For FY25, the company reported a net profit of ₹146 crore as compared with ₹128 crore in 2023-24.

The company said its board has approved the re-appointment of Ameera Shah as chairperson and whole-time director of the company for five years with effect from March 18, 2026.

The board also appointed Surendran Chemmenkotil, currently serving as CEO, as Managing Director for three years with effect from June 1, 2025.